Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.42 RON | +0.59% | +0.59% | +17.12% |
1st Jan change | Capi. | |
---|---|---|
+17.12% | 519M | |
+15.91% | 41.97B | |
+22.40% | 22.34B | |
+18.48% | 15.25B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-9.58% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology